Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Eledon Pharmaceuticals logo
$4.01 -0.06 (-1.47%)
(As of 11/22/2024 ET)

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Key Stats

Today's Range
$3.93
$4.17
50-Day Range
$2.44
$5.30
52-Week Range
$1.11
$5.54
Volume
178,667 shs
Average Volume
197,924 shs
Market Capitalization
$159.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Buy

Company Overview

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

ELDN MarketRank™: 

Eledon Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 404th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Eledon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($0.72) to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eledon Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eledon Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eledon Pharmaceuticals has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Eledon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.42% of the outstanding shares of Eledon Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently increased by 572.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eledon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eledon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.42% of the outstanding shares of Eledon Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently increased by 572.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eledon Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    16 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.70% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eledon Pharmaceuticals' insider trading history.
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELDN Stock News Headlines

Eledon Pharmaceuticals (NASDAQ:ELDN) Earns "Buy" Rating from HC Wainwright
Cantor Fitzgerald Issues Positive Estimate for ELDN Earnings
⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Eledon Pharmaceuticals Reports Strong Q3 2024 Results
See More Headlines

ELDN Stock Analysis - Frequently Asked Questions

Eledon Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, ELDN shares have increased by 122.8% and is now trading at $4.01.
View the best growth stocks for 2024 here
.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02.

Eledon Pharmaceuticals' top institutional shareholders include Zimmer Partners LP (3.62%), Geode Capital Management LLC (0.95%) and Clarity Capital Partners LLC (0.03%).
View institutional ownership trends
.

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/12/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELDN
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+299.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-116,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.92 per share

Miscellaneous

Free Float
35,016,000
Market Cap
$159.04 million
Optionable
Optionable
Beta
0.76
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ELDN) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners